Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott’s Simcor Significantly Lowers Non-HDL Cholesterol In SEACOAST Phase III Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Simcor, with a Feb. 20 user fee date, could face competition from two Merck investigational extended-release niacin combinations, including Cordaptive (laropiprant), with an anticipated FDA action date in Q2 2008.

You may also be interested in...

Abbott Partners With Solvay On Simcor Ahead Of Planned 2008 Launch

Solvay will provide sales support in the U.S. in addition to funding development and promotions for the Niaspan/simvastatin combination.

Merck’s Lipid-Lowering Combo Cordaptive Could Clear FDA In Mid-2008

The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.

Abbott Files Simcor With FDA

Combination of niacin and simvastatin will address LDL, HDL and triglycerides in a single pill.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts